Literature DB >> 2982747

Seroepidemiology of human T-lymphotropic retrovirus type I (HTLV-I) in residents of Niigata Prefecture, Japan. Comparative studies by indirect immunofluorescence microscopy and enzyme-linked immunosorbent assay.

T Aoki, H Miyakoshi, H Koide, T Yoshida, H Ishikawa, Y Sugisaki, M Mizukoshi, K Tamura, H Misawa, C Hamada.   

Abstract

A large sample of carriers of human T-lymphotropic retrovirus type I (HTLV-I) in Niigata Prefecture was examined for the detection of natural antibodies to HTLV-I-related antigens in sera using both indirect immunofluorescence microscopy (IFM) and enzyme-linked immunosorbent assay (ELISA). The present findings are based on multiple surveys, using each assay technique at least twice. Although Niigata Prefecture has been considered a non-endemic region for HTLV-I, Sado Island has been proven by this study to be a relatively endemic pocket within this non-endemic area. Seropositivity was highest in residents of Sado Island; 97/1, 117 (8.7%) by IFM and 33/1,061 (3.1%) by ELISA; followed by Niigata City, 18/650 (2.8%) by IFM and 16/638 (2.5%) by ELISA; and lowest in the remaining areas, 57/2,631 (2.2%) by IFM and 20/2,551 (0.8%) by ELISA. Seropositivity was demonstrated in 172/4,398 (3.9%) by IFM and 69/4,250 (1.6%) by ELISA in Niigata Prefecture taken as a whole. In general, the incidence of seropositive residents increased gradually with age. The sex difference was not significant. The serum samples tested were categorized into 4 groups; (1) IFM and ELISA both positive, (2) IFM positive but ELISA negative, (3) IFM negative but ELISA positive, and (4) IFM and ELISA both negative. By absorption tests, IFM and ELISA seemed to recognize different specific antibodies in sera; IFM recognized antibodies to HTLV-I-related cellular antigens in addition to HTLV-I viral antigens, but ELISA recognized antibodies to HTLV-I viral antigens alone. Thus, IFM detected a broader spectrum of antigens, resulting in recognition of more positive sera than those detected by ELISA.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982747     DOI: 10.1002/ijc.2910350304

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii.

Authors:  W A Blattner; A Nomura; J W Clark; G Y Ho; Y Nakao; R Gallo; M Robert-Guroff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 4.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

5.  Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto.

Authors:  J Chiavetta; J Nusbacher; F Tam; A Wall; J Steaffens; H Lee
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

6.  HTLV-1, HIV-1, hepatitis B and hepatitis delta in the Pacific and South-East Asia: a serological survey.

Authors:  R J Brindle; R P Eglin; A J Parsons; A V Hill; J B Selkon
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.